Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX EBITDA Margin
EBITDA as a percentage of revenue.
Apyx Medical CorporationNASDAQ: APYX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -3.4%
EBITDA Margin was -3.4% in Q1 FY2026, up 24.2 pp from a year earlier. On a trailing-twelve-month basis it was -4.4%, up 24.0 pp year over year. Over 3 fiscal years it widened by 40.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -5.2% for the fiscal year ending Dec 2026, up from -8.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -3.4%-5.9 pp QoQ
- Last fiscal yearDec 2025
- -8.7%+26.2 pp YoY
- LTMMar 2026
- -4.4%+24.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +24.2 pp | +3.3 pp | -20.9 pp |
| 1 year | +26.2 pp | +3.5 pp | -22.8 pp |
| 3 years | +40.8 pp | +11.3 pp | -29.5 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -8.7%
- Year-over-year change
- +26.2pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -8.7% | +26.2pp |
| FY2024 | 2024-12-31 | -34.9% | -0.3pp |
| FY2023 | 2023-12-31 | -34.6% | +14.8pp |
| FY2022 | 2022-12-31 | -49.4% | -20.8pp |
| FY2021 | 2021-12-31 | -28.7% | — |
EBITDA Margin vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 EBITDA Margin of -4.4% is the 3rd highest of the 7 companies compared; the peer median is -91.7%.
- Its year-over-year change of +24.0 pp is the 2nd highest of 7, against a peer median of +10.6 pp.
- Over three fiscal years its change of +40.8 pp compares with a peer median of +20.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 26.3% | +4.7 pp | +4.8 pp | |
| LTM Mar 2026 | 9.7% | +12.3 pp | +21.2 pp | |
| LTM Mar 2026 | -4.4% | +24.0 pp | +40.8 pp | |
| LTM Mar 2026 | -52.1% | +18.1 pp | +20.4 pp | |
| LTM Mar 2026 | -131.2% | +8.9 pp | +214.5 pp | |
| LTM Mar 2026 | -859.3% | +600.4 pp | +13170.1 pp | |
| LTM Mar 2026 | -54764.9% | -26826.7 pp | -22063.2 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding APYX) | -91.7% | +10.6 pp | +20.8 pp | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.52M | 44.51M | 52.35M | 48.1M | 52.84M |
| Cost of Revenue | 14.92M | 15.38M | 18.59M | 18.74M | 33.81M |
| Gross Profit | 33.6M | 29.13M | 33.76M | 29.36M | 19.03M |
| Gross Margin | 69.3% | 65.4% | 64.5% | 61.0% | 36.0% |
| Research & Development | 4.32M | 4.54M | 4.84M | 5.08M | 3.37M |
| Selling, General & Admin | 43.73M | 48.15M | 48.87M | 43.13M | 36.12M |
| Operating Expenses | 48.05M | 52.69M | 51.02M | 48.21M | 25.48M |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| EBITDA | (13.91M) | (22.01M) | (18.11M) | (16.8M) | (4.59M) |
| EBITDA Margin | -28.7% | -49.4% | -34.6% | -34.9% | -8.7% |
| Operating Income | (14.45M) | (23.56M) | (17.26M) | (18.85M) | (6.45M) |
| Operating Margin | -29.8% | -52.9% | -33.0% | -39.2% | -12.2% |
| Interest Income | 11K | 157K | 921K | 1.61M | 1.11M |
| Interest Expense | 10K | 15K | 2.48M | 5.91M | 5.59M |
| Other Income / Expenses | (372K) | 651K | (4.02M) | (4.46M) | (4.39M) |
| Income Before Tax | (14.82M) | (22.91M) | (21.28M) | (23.31M) | (10.84M) |
| Pre-Tax Margin | -30.5% | -51.5% | -40.7% | -48.5% | -20.5% |
| Income Tax Expense | 380K | 367K | (2.43M) | 252K | 270K |
| Net Income | (15.17M) | (23.18M) | (18.71M) | (23.46M) | (11.21M) |
| Net Margin | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% |
| EPS (Basic) | (0.44) | (0.67) | (0.54) | (0.66) | (0.27) |
| EPS (Diluted) | (0.44) | (0.67) | (0.54) | (0.66) | (0.27) |
| Weighted Avg Shares | 34.33M | 34.52M | 34.62M | 35.54M | 42.16M |
| Weighted Avg Shares (Diluted) | 34.33M | 34.52M | 34.62M | 35.54M | 42.16M |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.